Generic Truqap Availability
Last updated on Mar 13, 2025.
Truqap is a brand name of capivasertib, approved by the FDA in the following formulation(s):
TRUQAP (capivasertib - tablet;oral)
-
Manufacturer: ASTRAZENECA
Approval date: November 16, 2023
Strength(s): 160MG [RLD], 200MG [RLD]
Is there a generic version of Truqap available?
No. There is currently no therapeutically equivalent version of Truqap available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Truqap. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Patent 10,039,766
Issued: August 7, 2018
Inventor(s): Tomkinson Gary Peter
Assignee(s): AstraZeneca ABThe present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Patent expiration dates:
- April 16, 2033✓
- April 16, 2033
-
Protein kinase B inhibitors
Patent 10,059,714
Issued: August 28, 2018
Inventor(s): Johnson Paul David & Leach Andrew & Luke Richard William Arthur & Matusiak Zbigniew Stanley & Morris Jeffrey James
Assignee(s): AstraZeneca ABThe invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- October 10, 2028✓✓
- October 10, 2028
-
Protein kinase B inhibitors
Patent 10,654,855
Issued: May 19, 2020
Inventor(s): Johnson Paul David & Leach Andrew & Luke Richard William Arthur & Matusiak Zbigniew Stanley & Morris Jeffrey James
Assignee(s): AstraZeneca ABThe invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- October 10, 2028✓
- October 10, 2028
-
Patent 11,760,760
Patent expiration dates:
- October 10, 2028✓
- October 10, 2028
-
Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Patent 8,101,623
Issued: January 24, 2012
Inventor(s): Luke Richard William Arthur & Matusiak Zbigniew Stanley
Assignee(s): AstraZeneca ABThe invention relates to a novel group of compounds of Formula (I) or salts thereof:
Patent expiration dates:
- March 10, 2030✓✓✓
- March 10, 2030
-
Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Patent 8,809,336
Issued: August 19, 2014
Inventor(s): Berdini Valerio & Boyle Robert George & Saxty Gordon & Walker David Winter & Woodhead Steven John & Wyatt Paul Graham & Donald Alastair & Caldwell John & Collins Ian & Da Fonseca Tatiana FariaThe invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR; J-Jis N═C(R), (R)C═N, (R)N—C(O), (R)C—C(O), N═N or (R)C═C(R); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Qis a bond or a saturated Chydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRor NRCO where Ris hydrogen or methyl, or Ris a Calkylene chain linked to Ror a carbon atom of Qto form a cyclic moiety; and wherein the carbon atoms of the linker group Qmay optionally bear one or more substituents selected from fluorine and hydroxy; Qis a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Qis other than a bond; G is hydrogen, NRR, OH or SH provided that when E is aryl or heteroaryl and Qis a bond, then G is hydrogen; Ris hydrogen or an aryl or heteroaryl group, with the proviso that when Ris hydrogen and G is NRR, then Qis a bond; and R, R, R, Rand Rare as defined in the claims.
Patent expiration dates:
- October 25, 2025✓
- October 25, 2025
-
Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein
Patent 9,006,430
Issued: April 14, 2015
Inventor(s): Berdini Valerio & Boyle Robert George & Saxty Gordon & Walker David Winter & Woodhead Steven John & Wyatt Paul Graham & Donald Alastair & Caldwell John & Collins Ian & Da Fonseca Tatiana FariaThe invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR; J-Jis N═C(R), (R)C═N, (R)N—C(O), (R)C—C(O), N═N or (R)C═C(R); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Qis a bond or a saturated Chydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRor NRCO where Ris hydrogen or methyl, or Ris a Calkylene chain linked to R or a carbon atom of Qto form a cyclic moiety; and wherein the carbon atoms of the linker group Qmay optionally bear one or more substituents selected from fluorine and hydroxy; Qis a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group may optionally bear one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the G group; and provided that when E is aryl or heteroaryl, then Qis other than a bond; G is hydrogen, NRR, OH or SH provided that when E is aryl or heteroaryl and Qis a bond, then G is hydrogen; Ris hydrogen or an aryl or heteroaryl group, with the proviso that when Ris hydrogen and G is NRR, then Q is a bond; and R, R, R, Rand Rare as defined in the claims.
Patent expiration dates:
- October 25, 2025✓
- October 25, 2025
-
Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Patent 9,487,525
Issued: November 8, 2016
Inventor(s): Tomkinson Gary Peter
Assignee(s): AstraZeneca ABThe present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Patent expiration dates:
- April 16, 2033✓✓
- April 16, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 16, 2028 - NEW CHEMICAL ENTITY
More about Truqap (capivasertib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
